Founded in 2024, SJP targets RAS-driven, hormone-receptor-positive, and immune-refractory tumors with a novel pipeline of small molecules developed in our lab and ready to proceed with regulatory-grade trials. Backed by a Scientific Advisory Board that includes world-leading authorities in RAS and breast cancer biology, and immuno-oncology, SJP has established clinical partnerships with leading medical centers world-wide including UCSF, NCI, MD Anderson, Baylor College of Medicine, MSKCC, and McGill, to name a few. SJP Biotec GmbH | Precision Oncology | RAS-MAPK & Translation Biology | Switzerland | Remote-Flexible - The CMO/SVP of Clinical Development will serve as the company's most senior clinical leader, responsible for designing and executing a multi-indication clinical development strategy across one of the most compelling areas in the current oncology drug development field - ...
mehr